TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00907712

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: cardiac echo examination
Description: cardiac echo examination - before and after the surgery
Study: NCT02730689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP-R207

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DP-R207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Study: NCT01761175

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided infraclavicular block
Description: Ultrasound-guided single injection infraclavicular block: using an in-plane technique, 30 mL of mepivacaine 1.5% is injected at the posterior aspect of the artery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided axillary block
Description: Ultrasound-guided double injection axillary block: using an in-plane technique, 25 mL of mepivacaine 1.5% is injected postero-medial to the artery. During needle withdrawal, 5 mL of the same solution is injected close to the musculocutaneous nerve.
Study: NCT01825070

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Montmorency cherry concentrate
Description: Tart Montmorency cherry juice concentrate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Montmorency cherry concentrate
Description: Tart Montmorency cherry juice concentrate
Study: NCT05501223

Intervention type: OTHER
Group type: OTHER
Intervention: Medication review
Description: 30-60 minutes extra consultation regarding the patients drugs

Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: Standard care i.e. visit at the Dept. of Endocrinology.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: Standard care i.e. visit at the Dept. of Endocrinology.
Study: NCT02640573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: Treat symptomatic HbSC patients to MTD on hydroxyurea, and assess for clinical improvement using the AdultsQLTM 3.0 Sickle Cell Disease Module after 6 months at MTD, compared to entrance scores
Study: NCT00784641

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novel Bausch & Lomb daily disposable contact lenses
Description: Lenses to be worn and replaced daily for 2 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bausch & Lomb SofLens daily disposable contact lenses.
Description: Lenses to be worn and replaced daily for 2 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Johnson and Johnson 1-Day Acuvue Moist contact lenses
Description: Lenses to be worn and replaced daily for 2 weeks.
Study: NCT03211871

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Intraoperative intravenous dexmedetomidine infusion 0,5 mcg/kg/h

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline Flush, 0.9% Injectable Solution_#1
Description: Intraoperative intravenous normal saline infusion
Study: NCT00622973

Intervention type: OTHER
Group type: OTHER
Intervention: Imaging: diffusion-weighted MRI
Description: Diffusion-weighted MRI of the entire pelvis to detect lymph node metastases

Intervention type: OTHER
Group type: OTHER
Intervention: Sinerem (USPIO) enhanced MRI
Description: USPIO (Sinerem) will be administered intravenously immediately after the first MR examination at a dose of 2.6 mg Fe/kg body weight diluted in 100 ml of saline (optimal dose according to: (9, 10)) during a period of about 30 minutes under medical supervision. Postcontrast MR imaging will be performed 24-36 hours after contrast medium injection.
Study: NCT02796690

Intervention type: OTHER
Intervention: nasal swabs will be collected
Description: After formal consent, nasal swabs are collected for each participant. SA nasal carriage and its susceptibility to methicillin is determined using a rapid PCR technique (GenExpert, Cepheid). Each participant is asked to complete a short questionnaire regarding some demographic variables, smoking habits, long-term medication, sector of activity, and direct manipulation of the pathogen.
Study: NCT02345226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/RPV/TAF
Description: 200/25/25 mg FDC tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/RPV/TAF
Description: 200/25/25 mg FDC tablets administered orally once daily
Study: NCT01850849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 39652 cream

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cream vehicle
Study: NCT02846376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a fully humanized immunoglobulin 4 (IgG4) monoclonal antibody (mAb) which binds to PD-1 (CD279) with nanomolar affinity and shows a high degree of specificity for PD-1; blocking binding of PD-1 to PD-L1 and PD-L2. Nivolumab binds selectively to human PD-1 and does not bind to other members of the cluster of differentiation protein 28 (CD28) family.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a fully humanized immunoglobulin 4 (IgG4) monoclonal antibody (mAb) which binds to PD-1 (CD279) with nanomolar affinity and shows a high degree of specificity for PD-1; blocking binding of PD-1 to PD-L1 and PD-L2. Nivolumab binds selectively to human PD-1 and does not bind to other members of the cluster of differentiation protein 28 (CD28) family.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab is a recombinant, human mAb that binds to the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). Ipilimumab is an immunoglobulin 1 (IgG1) kappa immunoglobulin with an approximate molecular weight of 148 kilo-Daltons (kDa). Ipilimumab is produced in mammalian (Chinese hamster ovary) cell culture.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab is a recombinant, human mAb that binds to the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). Ipilimumab is an immunoglobulin 1 (IgG1) kappa immunoglobulin with an approximate molecular weight of 148 kilo-Daltons (kDa). Ipilimumab is produced in mammalian (Chinese hamster ovary) cell culture.
Study: NCT00096746

Intervention type: DRUG
Intervention: LPV/RTV + 2NRTIs
Description: Tablets, Oral, Variable, Twice daily, 48 weeks.

Intervention type: DRUG
Intervention: LPV/RTV + 2NRTIs
Description: Tablets, Oral, Variable, Twice daily, 48 weeks.
Study: NCT03156556

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mood Mechanic Course
Description: French-Canadian version of the Mood Mechanic Course. Performed by a professional translator (Bourret Translation Inc.) and reviewed by the research supervisor, Professor France Talbot, clinical psychologist as well with expertise in CBT.
Study: NCT02372292

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous furosemide
Description: Decongestant therapy for decompensated heart failure which may be administrated as intravenous bolus or infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous furosemide
Description: Decongestant therapy for decompensated heart failure which may be administrated as intravenous bolus or infusion
Study: NCT02883465

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Diaphragmatic ultrasound
Description: All patients will have a diaphragmatic ultrasound in the 4 hours before the extubation.~* a record of the right and left diaphragmatic cupolas run, with a chest approach and using a 4-5 MHz (megahertz) cardiac or abdominal sensor. 3 acquisitions for each side~* a record of the diaphragm thickening at the right and left apposition zones with a 10-12 MHz (megahertz) vascular sensor. 3 acquisitions for each side
Study: NCT03774693

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia with fentanyl boluses
Description: Patients will receive general anesthesia with Fentanyl boluses of 0.5 mcg.Kg-1 given to maintain MAP between 55-65 mmHg with a maximum dose of 3 mcg.Kg-1

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia with fentanyl boluses
Description: Patients will receive general anesthesia with Fentanyl boluses of 0.5 mcg.Kg-1 given to maintain MAP between 55-65 mmHg with a maximum dose of 3 mcg.Kg-1
Study: NCT01577407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nefopam
Description: Subjects will be infused intravenously with nefopam (20mg/2mL) over a course of 30 minutes in a supine position. There will be a single administration of IV 20 mg nefopam and IV placebo. Each intervention will occur on a separate day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nefopam
Description: Subjects will be infused intravenously with nefopam (20mg/2mL) over a course of 30 minutes in a supine position. There will be a single administration of IV 20 mg nefopam and IV placebo. Each intervention will occur on a separate day.
Study: NCT02626208

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nestorone®/Estradiol Contraceptive Vaginal Ring
Description: Three arms of contraceptive vaginal rings contain a fixed dose (200 mcg/day) of Nestorone® and escalating doses (75 µg/d, 100 µg/d, or 200 µg/d /day) of estradiol
Study: NCT03399006

Intervention type: DEVICE
Intervention: 2D ultrasound
Description: Trans-abdominal ultrasound examination was performed with the woman placed in a recumbent or semi recumbent position \& carried out for measurement of fetal CRL and diagnosis of any major fetal defects

Intervention type: DEVICE
Intervention: 2D ultrasound
Description: Trans-abdominal ultrasound examination was performed with the woman placed in a recumbent or semi recumbent position \& carried out for measurement of fetal CRL and diagnosis of any major fetal defects

Intervention type: DEVICE
Intervention: Doppler Ultrasound
Description: measurement of UtA-PI \& UtA-RI. A sagittal section of the uterus was obtained For the Doppler studies, and the cervical canal and internal cervical os were identified. The transducer was gently tilted from side to side and color flow mapping was used to identify each UtA along the side of the cervix and uterus at the level of the internal os.~When three similar consecutive waveforms had been obtained the UtA-PI and UtA-RI were measured, and the mean UtA-PI and UtA-RI of the left and right arteries were calculated.

Intervention type: DEVICE
Intervention: Doppler Ultrasound
Description: measurement of UtA-PI \& UtA-RI. A sagittal section of the uterus was obtained For the Doppler studies, and the cervical canal and internal cervical os were identified. The transducer was gently tilted from side to side and color flow mapping was used to identify each UtA along the side of the cervix and uterus at the level of the internal os.~When three similar consecutive waveforms had been obtained the UtA-PI and UtA-RI were measured, and the mean UtA-PI and UtA-RI of the left and right arteries were calculated.

Intervention type: DEVICE
Intervention: 3D ultrasound
Description: 3D transabdominal ultrasound of the Placental volume: the transducer with a full bladder and the transducer placed perpendicular to the placenta to see the entire placenta. The adjustments to 3D placental scan were an angle of 70° and a maximum region of interest that allowed the full placental surface. The external limits of the placenta were defined by the basal plate and the chorionic plate excluding the myometrium. Another acquisition was done, if the quality criteria were not attained.~After sonography, the placental volume was calculated with 4D View software (GE Healthcare) by a single operator. The calculation was done twice using the same image, and the time spent was recorded. The VOCAL mode with an angle of rotation of 30° was chosen; the axial plane was the reference; and the calipers were placed on either side of the placenta. With 6 planes, it was possible to reconstruct the volume measured in cubic centimeters.
Study: NCT03774693

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regional block
Description: Patients will receive trans-oral bilateral sphenopalatine ganglion block and trans-oral bilateral infraorbital nerve block.
Study: NCT04755296

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low level laser therapy
Description: Low level laser therapy was applied immediately before each aerobic exercise training session by using a multidiode cluster (with four diode spots; Polaris2, manufactured by Astar ABR, Poland) )on 12 sites on the lower limb (6 on quadriceps ( 2 centrally on rectus femoris and vastus intermedius,2 laterally on vastus lateralis, and two medially on vastus medialis), 4 on hamstrings and 2 on gastrocnemius) with the following parameters: 808 nm, continous output, 200 mW each diode (total of 800 mW) power output, 24 J energy on each site (6 J for each spot) , 40 seconds at each site (8 minutes of total treatment time in lower limb) and 288 J total energy delivered per lower limb, 48 irradiation points per lower limb ,3 sessions weekly for 12 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercises
Description: Aerobic exercise program consisted of walking on the treadmill at a rate of 3 sessions/week for 12 weeks, with each session lasting for 40 minutes in the form of warming up for 5 minutes at intensity of \<50% of the previously determined VO2max of each participant, 30 minutes of treadmill exercises at intensity of (70-85%) of the previously determined VO2max of each participant then 5 minutes cooling down at intensity of\<50% of the previously determined VO2max of each participant.
Study: NCT03399006

Intervention type: DEVICE
Intervention: 3D ultrasound
Description: 3D transabdominal ultrasound of the Placental volume: the transducer with a full bladder and the transducer placed perpendicular to the placenta to see the entire placenta. The adjustments to 3D placental scan were an angle of 70° and a maximum region of interest that allowed the full placental surface. The external limits of the placenta were defined by the basal plate and the chorionic plate excluding the myometrium. Another acquisition was done, if the quality criteria were not attained.~After sonography, the placental volume was calculated with 4D View software (GE Healthcare) by a single operator. The calculation was done twice using the same image, and the time spent was recorded. The VOCAL mode with an angle of rotation of 30° was chosen; the axial plane was the reference; and the calipers were placed on either side of the placenta. With 6 planes, it was possible to reconstruct the volume measured in cubic centimeters.
Study: NCT04755296

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercises
Description: Aerobic exercise program consisted of walking on the treadmill at a rate of 3 sessions/week for 12 weeks, with each session lasting for 40 minutes in the form of warming up for 5 minutes at intensity of \<50% of the previously determined VO2max of each participant, 30 minutes of treadmill exercises at intensity of (70-85%) of the previously determined VO2max of each participant then 5 minutes cooling down at intensity of\<50% of the previously determined VO2max of each participant.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional physical therapy program
Description: Patients were received traditional physical therapy program in the form of (stretching and strengthening exercises for all affected areas, diaphragmatic breathing exercises and activities of daily living).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional physical therapy program
Description: Patients were received traditional physical therapy program in the form of (stretching and strengthening exercises for all affected areas, diaphragmatic breathing exercises and activities of daily living).
Study: NCT03356158

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CPGJ602
Description: Injection, q.w., 20 mg: 100 ml
Study: NCT02010294

Intervention type: GENETIC
Intervention: DNA samples, GAS strains
Description: DNA samples,GAS strains

Intervention type: GENETIC
Intervention: DNA samples, GAS strains
Description: DNA samples,GAS strains
Study: NCT01273857

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous cardiac progenitor cell transplantation
Description: Patients will receive 0.3 million / kg of autologous cardiac progenitor cells via intracoronary delivery 1 month after cardiac surgery. Follow-up visits 3 months to 1 year after cell injection will need to prospectively verify the clinical, laboratory, and safety-related data.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: staged shunt procedure
Description: Norwood-Glenn, Glenn, or Fontan procedure will be applied

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: staged shunt procedure
Description: Norwood-Glenn, Glenn, or Fontan procedure will be applied
Study: NCT02219308

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paracervical Block (PCB)
Description: Drug: 1% Lidocaine Hydrochloride~Injection of 2 mL 1% buffered lidocaine solution at anterior lip of cervix and 18 mL 1% buffered lidocaine solution evenly distributed between 4 o'clock and 8 o'clock positions of cervix with standard 22 gauge spinal needle.~IUD placement then proceeds
Study: NCT02219308

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: No Paracervical Block (Sham PCB)
Description: Drug: 1% Lidocaine Hydrochloride~Injection of 2 mL 1% buffered lidocaine solution at anterior lip of cervix with standard 22 gauge spinal needle. Capped spinal needle is then held against the cervix at 4 o'clock and 8 o'clock positions of cervix, lightly so as not to cause blanching, indentation, or pain.~IUD placement then proceeds
Study: NCT03992313

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community-based HCV rapid test
Description: HCV rapid tests will be done in the village
Study: NCT02345226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EFV/FTC/TDF Placebo
Description: Tablets administered orally once daily
Study: NCT01201044

Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine, Nedaplatin, iV
Description: Gemcitabine, Injection, 1000mg/m2, D1 \& D7/ 4weeks/cycle, 2 cycles Nedaplatin, Injection, 75mg/m2, d1/4weeks/cycle, 2 cycles.

Intervention type: RADIATION
Group type: OTHER
Intervention: 3DCRT
Description: non-PD Patient will be treated with 3DCRT after 2 cycles of chemo.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3DCRT
Description: non-PD Patient will be treated with 3DCRT after 2 cycles of chemo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine，Nedaplatin, BAI
Description: Drug: Gemcitabine, Nedaplatin, iV~Gemcitabine, Injection, 1000mg/m2, D1/4weeks/cycle, 2 cycles Nedaplatin, Injection, 75mg/m2, d1/4weeks/cycle, 2 cycles. BAI
Study: NCT02345226

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EFV/FTC/TDF
Description: 600/200/300 mg FDC tablets administered orally once daily
Study: NCT02416544

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lunch which is calorie-restricted and low-salt
Description: Comparison of different duration of feeding lunch which is calorie-restricted and low-salt

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lunch which is calorie-restricted and low-salt
Description: Comparison of different duration of feeding lunch which is calorie-restricted and low-salt

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lunch which is calorie-restricted and low-salt
Description: Comparison of different duration of feeding lunch which is calorie-restricted and low-salt
Study: NCT02367885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-850 0.5 mL injection
Description: TAK-850 injection
Study: NCT02345226

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FTC/RPV/TAF Placebo
Description: Tablets administered orally once daily
Study: NCT01571310

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Omitted Breakfast
Description: Experimental:The patients in Omitted Breakfast day will omit the breakfast and will continue the overnight fast until lunch. They will eat only lunch (700 kcal) at 13:30 and dinner (700 kcal) at 19:00

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Omitted Breakfast
Description: Experimental:The patients in Omitted Breakfast day will omit the breakfast and will continue the overnight fast until lunch. They will eat only lunch (700 kcal) at 13:30 and dinner (700 kcal) at 19:00

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breakfast
Description: In the Active Comparator: The patients in the Breakfast day will consume breakfast (700 kcal) at 8:00 , lunch (700 kcal) at 13:30 and dinner (700 kcal) at 19:00~(YesB): The patients in YesB will eat all three mealswill consume three meals:

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breakfast
Description: In the Active Comparator: The patients in the Breakfast day will consume breakfast (700 kcal) at 8:00 , lunch (700 kcal) at 13:30 and dinner (700 kcal) at 19:00~(YesB): The patients in YesB will eat all three mealswill consume three meals:
Study: NCT01844557

Intervention type: OTHER
Intervention: Swallowing Exercises
Description: Participants perform 3 swallowing exercises.

Intervention type: OTHER
Intervention: Swallowing Exercises
Description: Participants perform 3 swallowing exercises.

Intervention type: OTHER
Intervention: Swallowing Exercises
Description: Participants perform 3 swallowing exercises.

Intervention type: BEHAVIORAL
Intervention: Symptom Inventory
Description: Participants complete an M.D. Anderson Symptom Inventory for Head and Neck Cancer Patients before swallowing exercise procedure.

Intervention type: BEHAVIORAL
Intervention: Symptom Inventory
Description: Participants complete an M.D. Anderson Symptom Inventory for Head and Neck Cancer Patients before swallowing exercise procedure.

Intervention type: BEHAVIORAL
Intervention: Symptom Inventory
Description: Participants complete an M.D. Anderson Symptom Inventory for Head and Neck Cancer Patients before swallowing exercise procedure.

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Participants fill out 3 questionnaires after swallowing exercises. The questionnaires will take about 10 minutes to complete.

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Participants fill out 3 questionnaires after swallowing exercises. The questionnaires will take about 10 minutes to complete.

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Participants fill out 3 questionnaires after swallowing exercises. The questionnaires will take about 10 minutes to complete.
Study: NCT01372228

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hematopoietic stem cell infusion
Description: Enriched hematopoetic stem cell infusion
Study: NCT03815474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anlotinib
Description: Anlotinib 12 mg once daily for 14 days tablet by mouth ; epirubicin 30mg/m2 intravenous injection from 1 day to 2 , ifosfamide 1.8g/m2 intravenous injection from 1day to 5day with 6 cycles. Anlotinib 12 mg once daily for 14 days tablet by mouth to progressive disease
Study: NCT03086278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AST-008
Description: AST-008 is a toll-like receptor 9 agonist.